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Abstract
Metabolic Syndrome (MetS) represents a constellation of markers that indicates a predisposition to diabetes, cardiovascular
disease and other pathologic states. The definition and treatment are a matter of current debate and there is not general
agreement on a precise definition or, to some extent, whether the designation provides more information than the individual
components. We consider here five indicators that are central to most definitions and we provide evidence from the literature
that these are precisely the symptoms that respond to reduction in dietary carbohydrate (CHO). Carbohydrate restriction is
one of several strategies for reducing body mass but even in the absence of weight loss or in comparison with low fat
alternatives, CHO restriction is effective at ameliorating high fasting glucose and insulin, high plasma triglycerides (TAG), low
HDL and high blood pressure. In addition, low fat, high CHO diets have long been known to raise TAG, lower HDL and, in the
absence of weight loss, may worsen glycemic control. Thus, whereas there are numerous strategies for weight loss, a patient
with high BMI and high TAG is likely to benefit most from a regimen that reduces CHO intake. Reviewing the literature, benefits
of CHO restriction are seen in normal or overweight individuals, in normal patients who meet the criteria for MetS or in patients
with frank diabetes. Moreover, in low fat studies that ameliorate LDL and total cholesterol, controls may do better on the
symptoms of MetS. On this basis, we feel that MetS is a meaningful, useful phenomenon and may, in fact, be operationally defined
as the set of markers that responds to CHO restriction. Insofar as this is an accurate characterization it is likely the result of
the effect of dietary CHO on insulin metabolism. Glucose is the major insulin secretagogue and insulin resistance has been tied
to the hyperinsulinemic state or the effect of such a state on lipid metabolism. The conclusion is probably not surprising but has
not been explicitly stated before. The known effects of CHO-induced hypertriglyceridemia, the HDL-lowering effect of low fat,
high CHO interventions and the obvious improvement in glucose and insulin from CHO restriction should have made this
evident. In addition, recent studies suggest that a subset of MetS, the ratio of TAG/HDL, is a good marker for insulin resistance
and risk of CVD, and this indicator is reliably reduced by CHO restriction and exacerbated by high CHO intake. Inability to
make this connection in the past has probably been due to the fact that individual responses have been studied in isolation as
well as to the emphasis of traditional therapeutic approaches on low fat rather than low CHO.
We emphasize that MetS is not a disease but a collection of markers. Individual physicians must decide whether high LDL, or
other risk factors are more important than the features of MetS in any individual case but if MetS is to be considered it should
be recognized that reducing CHO will bring improvement. Response of symptoms to CHO restriction might thus provide a new
experimental criterion for MetS in the face of on-going controversy about a useful definition. As a guide to future research, the
idea that control of insulin metabolism by CHO intake is, to a first approximation, the underlying mechanism in MetS is a testable
hypothesis.
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Introduction
An association between obesity, diabetes, cardiovascular
disease and hypertension has been recognized for some
time. Reaven's 1988 Banting lecture is generally consid-
ered a turning point in codifying a unifying principle
under the name of MetS or Syndrome X (Reviews: [1-7].
Although there is no universally accepted definition or
mechanism, (Table 1) a rough common denominator is
the set of five features: obesity (high body weight, BMI
and/or waist circumference), high glucose and insulin lev-
els, low HDL, high TAG and high blood pressure. Involve-
ment of insulin resistance is generally a common feature
and a likely causative agent for at least some of the symp-
toms. A subset of these metabolic markers, the TAG:HDL
ratio, has been proposed as a simple marker for identify-
ing insulin resistance [8]. It has recently been questioned
whether the risk attributed to MetS is greater than the sum
of the individual symptoms [9] and, ironically, Reaven
has taken the "Con" side on a debate on the viability and
diagnostic usefulness of the concept [10,11]. Nonetheless,
there seems little controversy on the inherent potential for
risk in the individual components.
In reading recent reviews of low CHO diets [12,13], we
were struck by the fact that the symptoms of MetS are pre-
cisely the ones targeted by diets that restrict CHO. This
effect is not entirely surprising since it has been known
that dietary CHO tends to raise glucose, insulin, and TAG
and lower HDL and conversely, replacing CHO with
monounsaturated fat or with fat and protein improves
glycemic control and dyslipidemia expressed as elevated
TAG and lowered HDL. Nevertheless, most formal guide-
lines and clinical papers have not emphasized CHO
restriction as a viable approach to treating MetS or the
individual components [14,15] and although several
authors have indicated an association between MetS and
CHO restriction in passing [5,13,16,17] the explicit con-
nection has not been made.
In this study we have isolated five features that are com-
mon to almost all definitions. Waist circumference is
probably the currently preferred measure for obesity, but
most of the literature provides data on body mass and we
have used that measure. We have collected information in
the literature supporting the notion that these symptoms
are specifically ameliorated by reduction in dietary CHO,
and to the extent that they have been directly compared,
low CHO strategies appear to have an advantage over low
fat diets or simple calorie reduction. We conclude that
response to CHO restriction may be an operational defi-
nition for MetS and that a likely mechanism is the control
of insulin metabolism. Finally, we side with those who
maintain that MetS is a real thing in the sense that the con-
comitant appearance of several symptoms may provide
different recommended strategies than the isolated fac-
tors. It is important to point out, however, that MetS is not
a disease but a complex of markers and practitioners may
decide that LDL or other factors are more important for
individual patients and in these cases other therapies will
be appropriate. On the other hand, reliance on LDL as a
prime indicator must be tempered by the importance of
LDL particle phenotypes which, in turn, correlate with
TAG and HDL levels, a subset of MetS markers.
CHO restriction for weight loss
It is sometimes stated that MetS is caused by obesity [1].
In our view, this is only one of several possible theories
and would assume that we know the causes of obesity. It
is at least plausible that obesity and the features of MetS
arise in parallel from disruptions of insulin metabolism
(possibly a consequence of high insulin due to chronic
high dietary CHO). Also a high prevalence of so called
metabolically obese-normal-weight individuals with
MetS has long been known [18]. In any case, it is generally
agreed that the first line of attack against MetS or frank
diabetes should be reduction in body mass. The method
for attaining this weight loss, however, is more controver-
Table 1: NCEP-ATP III and WHO Definitions of Metabolic Syndrome. Other definitions in references [1], [4] and [90].
ATP III Definition
Any three or more of the following criteria:
a) Waist circumference: >102 cm in men, >88 cm in women
b) Serum triglycerides: ≥150 mg/dL
c) HDL-cholesterol: <40 mg/dL in men, < 50 mg/dL in women
d) Blood pressure: ≥130/85 mm Hg
e) Serum glucose: >110 mg/dL
WHO Definition
Diabetes or IFG or IGT or insulin resistance, plus at least two of the following criteria
a) Waist-to-hip ratio: >0.90 in men, >0.85 in women
b) Serum triglycerides: >150 mg/dL or HDL-cholesterol: <35 mg/dL in men and <40 mg/dL in women
c) Blood pressure: >140/90 mmHg
d) Urinary albumin excretion rate > 20 µg/min or albumin/creatinine ratio >30 mg/gN
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Table 2: 
CHANGE
Reference # Subjects Duration CHO (g/d) weight (%) HDL (%) TAG (%) TAG/HDL (%) Glucose (%) Insulin (%)
Rickman et al. 1974 1 Normal Weight Men/Women 3–17 d 7 -4.9 -11.4
LaRosa et al. 1980 2 Obese Men/Women 8 wk 6 -8.3 -5.7 -32.6 -29.9
Phinney et al. 1980 3 Obese Men/Women 6 wk <20 -11.8 -24 -16.3 -57.3
Phinney et al. 1983 4 Normal Weight Men 4 wk <20 0.2 0 -26 -7.7 -23.3
Newbold, 1988 5 Men 3–12 mo 9.6 -34.8 -40.5
Volek et al. 2000 6 Normal Weight Men 8 wk 39 -5.4 10.0 -54.9 -56.9 -3.4 -28.0
Sharman et al. 2002 7 Normal Weight Men 6 wk 46 -2.8 11.5 -33 -39.9 -0.2 -34.2
Meckling et al. 2002 8 Obese Women 8 wk 71 -6.1 4.3 -40.3 -4.1 0.0
Westman et al. 2002 9 Obese Men/Women 6 mo Ad Lib -10.3 19.2 -43.1 -53.6
Dashti et al. 2003 10 Obese Men/Women 12 wk 20 to 30 -13.4 8.3 -50 -53.9 -37.1
Hays et al. 2003 11 Obese Men/Women w/ CVD 6 wk Ad Lib -5.2 -2.9 -39.9 -38.1 -7.4 -30.5
Obese Women PCOS 24 wk Ad Lib -14.3 0.4 -18.5 -18.8 5.7 -49.6
Obese Women Reactive Hypoglycemia 52 wk Ad Lib -19.9 3.4 -13.3 -33.2
Dashti et al. 2004 12 Obese Men/Women 24 wk 40 -14.2 20.4 -60.4 -67.1 -22.6
Boden et al. 2005 13 Obese/diabetic men/women 14 days 21 -1.8 -2 -35 -33.8 -16.0
Table 3: 
CHANGE
Reference # Subjects Duration Diet CHO (g/d) weight (%) HDL (%) TAG (%) TAG/HDL (%) Glucose (%) Insulin (%)
Sharman et al.2002 1 Normal Weight Men 6 wk Ketogenic 46 -2.8 11.5 -33.0 -39.9 -0.2 -34.2
6 wk Low-Fat 271 0.5 0.0 -5.3 -5.3 1.8 13.0
Volek et al. 2003 2 Normal Weight Women 4 wk Ketogenic 43 -2.0 32.0 -30.2 -47.2 -1.9 11.6
4 wk Low-Fat 249 -1.3 -7.7 3.8 0.5 -5.3 18.7
Allick et al. 2004 3 Type 2 Diabetics 2 wk Ketogenic 0 0 23.5 -43.9 -55 -16.9 -16.7
2 wk Low-Fat 775Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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sial. Studies in the literature imply that a low fat diet is a
kind of standard although much recent evidence has indi-
cated the value of strategies based on carbohydrate restric-
tion. Whereas low fat diets for calorie reduction can
undoubtedly be effective for many people, we feel that
they cannot be taken as an established standard; to our
knowledge, there has never been a long term study where
a low fat diet was instituted in the absence of confounding
features such as cessation of smoking and exercise. Also,
fat restriction per se does not enhance long-term (one year
or longer) weight loss or prevent regain of weight [19] and
the record of compliance is modest at best [20]. Most
important, the fact that, in the obesity and diabetes epi-
demic, fat consumption went down (for men, the abso-
lute amount) and carbohydrate consumption went up
[21,22], means that other approaches should be consid-
ered. Insofar as isocaloric comparisons have been made,
low CHO diets do at least as well, and usually better, than
low fat diets (see below). Most striking, in ad lib. trials,
subjects on low CHO diets show a spontaneous reduction
in calories without any dissatisfaction [23-25], a goal that
is universally considered desirable but generally recog-
nized as difficult to impose by cognitive admonitions on
calorie restriction per se [26]. In general, published data
support the idea that low CHO diets are at least as effec-
tive as other weight reduction methods. Further, experi-
mental results show an improvement in lipid outcomes
(discussed below), no damage to normal kidneys [27], the
potentially beneficial rather than deleterious effects of
ketone bodies [28-30] and the prevalence of strategies
based on low glycemic index [31,32] or reduction of
refined CHO or sweets, all approximations of low CHO
diets.
Despite increased acceptance of low carbohydrate regi-
mens, it is important to point out that there is a tendency
to equate any kind of carbohydrate restriction with the
popular Atkins diet [33] and to equate the Atkins diet with
a recommendation for high fat and with high saturated
fat, in particular. There are, however, many strategies for
reducing carbohydrate intake both clinically and in popu-
lar diets [34,35]. Whereas high fat is permitted on the
Atkins diet and other low carbohydrate diets it is not spe-
cifically recommended; as noted above, at least three pub-
lished studies [23-25] and much anecdotal evidence
suggests that, in practice, the major effect is reduction in
carbohydrate intake with limited replacement with either
fat or protein. In addition, although a deleterious effect of
saturated fat, at least in the absence of CHO control, is
established [36,37], it has been known since the Seven
Countries study [38] that total dietary fat does not corre-
late with cardiovascular risk and the two effects should
not be confused [36,37]. In any case, no particular diet is
recommended here; the studies cited include all kinds of
interventions, and the underlying rationale is the effect of
carbohydrate on insulin. The principle espoused here
should be evaluated on this basis.
It seems that a prudent statement of the state of affairs
would be that, at this point, dieters have many strategies,
none perfect, for weight loss and CHO restriction of some
kind is one of them.
CHO restriction and MetS
Our argument in the following exposition is that a patient
presenting with a high BMI or large waist line has several
options for weight loss. Many factors, including physician
experience, ethnic background, personal taste and genetic
profile, will determine the first one to be tried. A patient
presenting with high BMI and high TAG may have a clear
best strategy because of the known benefit of CHO reduc-
tion and the accepted deleterious effect of high CHO
intake. Data from the literature suggests that a patient
with more than two of the symptoms of MetS or the par-
ticular combination of high TAG/HDL ratio should clearly
try CHO restriction as a first strategy. Conversely, the
patient with high BMI and high LDL might sensibly try a
low fat strategy first. We provide a summary of cases in
which CHO restriction is beneficial in the treatment of
MetS or its individual symptoms. The review is meant to
be representative rather than comprehensive but we think
that the wide variety of cases studied and the range of con-
ditions against a background of accepted effects of carbo-
hydrate on the relevant parameters, provides a strong case
for our thesis. In addition, the generally consistent benefit
of CHO restriction allows a possible further basis for iden-
tifying the common thread in MetS if such truly exists.
CHO restriction improves symptoms of MetS
Table 2 (Table 2) shows the results of single arm studies
in which CHO-restricted diets of various compositions
and duration were used (for summary of details see, e.g.,
[39-41]). The regimens include very low CHO ketogenic
diets (< 50 g/d) and encompasses subjects that were over-
weight, presented with symptoms of MetS, or were dia-
betic. It is clear that CHO restriction is effective in
relieving these symptoms. Noteworthy is the recent study
of Boden [23] which, while short in duration, carefully
measured relevant parameters in patients with diabetes.
Patients in this study spontaneously decreased food
intake to a substantial degree, were satisfied with the diet,
did not show substantial water loss and several were able
to reduce or terminate medication.
Improvement is seen in the absence of weight loss
Since it is known that weight loss generally improves
MetS, it is important to ask whether beneficial metabolic
responses to low CHO diets are dependent on weight loss.
The question was specifically addressed by Volek's group
[42,43] in normal-weight men and women encouraged toNutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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maintain their weight and by Allick and colleagues in
patients with diabetes mellitus type 2 [44] (Table 3). The
studies in normal weight women [43] and type 2 diabetics
[44], in particular, used a cross-over experimental design
removing the confounding effect of group differences.
These studies were also well-controlled. In the case of
Allick, formula was used and, in the studies by Volek,
compliance was documented by measuring elevation of
serum and urine ketones, thereby eliminating dietary
reporting errors as a confounding factor. Improvement in
the TAG/HDL ratio ranged from 40 to 55%. In summary,
a low CHO regimen clearly improves MetS relative to low
fat diets even in the absence of weight loss.
In addition to studies in which weight maintenance was a
feature of experimental design it is important to consider
data reported by Foster [45] (Figure 1, (Table 4), who
compared low CHO and LF diets. It is widely quoted that
the low CHO diet is better at 6 months but that there is no
difference in the diets at 12 months. However, it has been
pointed out [12] that the particular form of low CHO diet
used (Atkins diet) allowed increases in CHO consump-
tion as the trial progressed indicating that it is likely this
reintroduction of CHO that predisposes to long-term
regain in weight. Most notable in this study, is that the
improvement in lipid profile persisted (Figure 1, (Table 4)
even after the effect on weight loss disappeared.
In ad lib. comparisons low CHO diets do better than low 
fat diets for weight loss and MetS
At this point, we have established that CHO restriction
improves MetS and that this can be independent of weight
loss. Weight loss can, of course, occur with low fat diets
and we next consider the extent to which one or the other
strategy is more effective. (Table 4) summarizes results of
several studies in the literature demonstrating that low
CHO diets generally do better than low fat diets in ad lib.
comparisons. Although there is great variability, a pattern
of better responses on very low CHO is evident. It is nota-
ble that Samaha et al studied a population in which 39 %
had diabetes and 43% had MetS [46].
Figure 1 shows data from the study of Foster, et al. [45]
and, as noted above, despite the relative similarity in
weight loss, the markers of MetS were more favorable in
the low CHO arm than the LF arm.
In isocaloric comparisons, low CHO diets do better than LF 
diets for weight loss
Because weight reduction is considered the first line of
attack in MetS or frank diabetes it is worth considering the
record of low CHO diets on this parameter alone. It is gen-
erally agreed that the major effect of a low CHO diet is a
spontaneous reduction in calories. In studies mentioned
above, subjects did not significantly increase fat or protein
intake but merely removed CHO from their diets [23-25].
Foster and Samaha also attributed the better performance
of low CHO arm to decreased caloric intake, although this
was not actually measured.
Beyond spontaneous caloric reduction, however, it has
been shown that the macronutrient composition of the
diet can affect the efficiency of energy utilization and
greater efficacy, the so-called metabolic advantage, of low
CHO diets compared to LF diets has been the subject of
several reports (Reviews: [39,41]. It has long been argued
that there must be some mistake because it is physically
impossible and would violate the laws of thermodynam-
ics. We have shown this argument is based on misunder-
standing of the laws of thermodynamics [39,47-49] and
the effect of variable efficiency is now better accepted
[50,51]. The precise conditions that allow the so-called
metabolic advantage to occur are not known although
Cornier, et al. [51] have suggested that those subjects with
insulin resistance will show a metabolic advantage on a
low CHO diet whereas those who are insulin sensitive do
better on low fat. This is consistent with the proposal here,
namely that MetS, where insulin-resistance is generally
considered a major component, can be defined by the
response to CHO restriction. The study of Cornier, et al.
[51] had only a small number of subjects and the low
CHO arm was not particularly low (40%) but their theory
follows from the general rationale of the effect of CHO on
Comparison of features of Metabolic Syndrome on low car- bohydrate vs. high carbohydrate diets Figure 1
Comparison of features of Metabolic Syndrome on 
low carbohydrate vs. high carbohydrate diets. Data 
from reference [45].N
u
t
r
i
t
i
o
n
 
&
 
M
e
t
a
b
o
l
i
s
m
 
2
0
0
5
,
 
2
:
3
1
h
t
t
p
:
/
/
w
w
w
.
n
u
t
r
i
t
i
o
n
a
n
d
m
e
t
a
b
o
l
i
s
m
.
c
o
m
/
c
o
n
t
e
n
t
/
2
/
1
/
3
1
P
a
g
e
 
6
 
o
f
 
1
7
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 4: 
CHANGE
Reference # Subjects Duration Diet CHO (g/d) weight (%) HDL (%) TAG (%) TAG/HDL (%) Glucose (%) Insulin (%) DBP
(mm Hg)
Brehm et al. 2003 1 Obese Women 6 mo Low-CHO 41–97 -9.3 13.4 -23.4 -32.4 -9.1 -14.8 -5
LF 163–169 -4.2 8.4 1.6 -6.3 -4.0 -23.0 -1
Sondike et al. 2003 2 Overweight Adolescents 12 wk Low-CHO 37 -10.7 8.7 -40.5 -45.2
LF 154 -4.1 4.2 -5.4 -9.2
Samaha et al. 2003 3 Obese Men/Women 6 mo Low-CHO 150 -4.5 0.0 -20.2 -20.2 -8.6 -27.3
LF 201 -1.4 -2.4 -4 -1.6 -1.6 5.6
Foster et al. 2003 4 Obese Men/Women 1 yr Low-CHO ad lib -7.3 18.2 -28.1 -29.5
LF ad lib -4.5 1.4 0.7 -2.6
Volek et al. 2004 5 Overweight Women 4 wk Low-CHO 29 -3.9 1.3 -23 -28.3 -3.8 -8.8
LF 186 -1.4 -8.6 -11.2 -4.2 1.3 23.2
Sharman et al. 2004 6 Overweight Men 6 wk Low-CHO 36 -5.6 -3.3 -44.1 -42.3 -5.8 -41.5
LF 224 -3.6 -6.6 -15 -8.3 -5.2 -28.1
Brehm et al. 2004 7 Obese Women 4 mo Low-CHO 69 -10.8 16.3 -37.3 -46.1 -9
LF 174 -6.8 4.5 -10.3 -14.2 -3
Meckling et al. 2004 8 Obese Men/Women 10 wk Low-CHO 59 -7.7 12.2 -29.4 -37.1 -8.0 -28.7 -6.1
LF 225 -7.4 -15.4 -25.4 -11.8 -10.2 -3.3 -5
Stern et al. 2004 9 Obese Men/Women 1 yr Low-CHO 120 -3.9 -2.8 -28.6 -26.8
LF 230 -2.3 -12.3 2.7 29.6
Yancy et al. 2004 10 Obese Men/Women 24 wk Low-CHO 30 -12.3 9.8 -47.2 -51.8 -6
LF 198 -6.7 -2.9 -14.4 -12.1 -5.2
Aude et al. 2004 11 Obese Men/Women 12 wk Low-CHO ad lib -6.2 -2.6 -23.2 -21.1
LF ad lib -3.4 -7 -10.5 -3.8
Seshadri et al. 2004 12 Obese Men/Women 6 mo Low-CHO 113 (-8.5) -2.4 -7.4 -40
LF 198 (-3.5 kg) -2.4 -2.3 11.2
McAuley et al. 2004 13 Obese Women 8 wk Low-CHO 41 -6.9 0.9 -38.8 -44.2 -5.9 -39.3
LF 172 -4.4 -6 -17.5 -15.1 -0.1 -28.4
Mod-PRO 130 -5.8 -4.1 -33.9 -31.8 -3.9 -24.4
Dansinger et al. 2004 14 Obese Men/Women 2 mo Low-CHO 103 -4.7 8.8 -27.6 -26.20 -10 -29.5
Mod-PRO 158 -4.6 4.6 -34 -30.50 -9.3 -27.7
LF 183 -4.3 -0.6 -7.1 -5.60 -5.7 -11
UltraLF 230 -4.9 -10.9 -0.6 8.40 -3.5 -7.7Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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energy efficiency. The factors that determine whether a
metabolic advantage can play a role in a CHO restricted
diet is unknown but given that the insulin resistance asso-
ciation is reasonable, it would seem that some form of
CHO restriction is one of the standard, if not preferred
attacks on obesity where MetS is suspected.
Figure 2 shows data from Golay, et al. [52] This study is
widely quoted as an example of how weight loss is inde-
pendent of macronutrient composition; although the low
CHO arm did better in weight loss, this was judged not
significant. This may well be an experiment in which met-
abolic advantage does not occur – the effect is only possi-
ble, not required [39]. It is clear, however, from the figure
that there is improvement in TAG and insulin and Golay's
conclusion was that "...considering the greater improve-
ment of fasting blood insulin, the glucose/insulin ratio
and blood triglyceride, the low carbohydrate diet (25%)
could be more favourable in the long-term [52]."
Is this new?
In Edgar Allan Poe's detective story The Purloined Letter,
the police search the apartment for a missing blackmail
note [53]. In the end, Poe's detective, Auguste Dupin
reveals that it had been in plain view on the fireplace all
along. The effect of CHO reduction on the symptoms of
MetS has, in fact, been visible for some time. In a classic
review in 1986, Reaven demonstrated the relative effects
of 40% and 55% CHO [54]. Figure 3 shows data from that
study: day long glucose, insulin and TAG levels were
improved by the low CHO diet. Of interest, is that fasting
glucose is not different on the two diets but there is a clear
difference in the time course, common to several low
CHO interventions (Table 3)). Reaven's experiment sug-
gests that a nutritional approach to MetS is possible by
lowering dietary CHO. The experiment should sensibly
have spurred research to see whether still lower CHO had
further beneficial effect. It took many years, however,
before this was done.
Substitution of protein for CHO improves MetS
Despite the evidence from Reaven's experiment, a barrier
to progress in understanding the role of CHO restriction
Effect of carbohydrate on parameters of Metabolic Syndrome Figure 3
Effect of carbohydrate on parameters of Metabolic 
Syndrome. Comparison of 40% CHO (blue) and 55% (red) 
CHO diets. Data from [54].
Per cent change in response to diet Figure 2
Per cent change in response to diet. Low carbohydrate 
(dark blue 25 % CHO) and low fat diets(light blue: 45 % 
CHO). Data from Golay, et al. [52].Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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was the accepted idea that high fat was unhealthy. At the
same time, it was thought that an increase in protein
would be deleterious for type 2 diabetics because of the
increase in glucose due to gluconeogenesis. Nuttall and
Gannon have summarized the history of this problem and
work in their lab showed that, in fact, glycemic control
was enhanced by a diet that was 40 % CHO, with protein
replacing part of the carbohydrate [55,56]. Most recently,
this group has shown the benefit of a 20 % CHO diet with
higher protein [57]. Results in Figure 4 show a pattern
similar to Reaven's but much more dramatic. Similar strik-
ing differences in the control of insulin and TAG were also
demonstrated.
Explicit low-fat/high CHO interventions exacerbate MetS
In the approach taken here, we see dietary fat as playing a
largely passive role (not withstanding differences between
different fats) and the disposition of dietary fat is control-
led by insulin and other hormones that, in turn, depend
on dietary CHO which we take as the controlling variable.
Thus, characterizing a low CHO diet as high fat [58,59]
ignores the question about the underlying mechanism; we
have recently raised the question of whether "high fat" is
a meaningful description in the absence of information
about CHO [60]. In the cases we discuss next, the focus is
interventions described or designed as low fat. Our point
here, however, is that although low fat diets exacerbate the
markers of MetS, it is likely the high CHO rather than the
fat level that is important.
A very influential paper by Garg, et al. [61] describes a four
center randomized study of patients with type 2 diabetes
receiving glipizide treatment. The study compared diets
where monounsaturated fat was substituted for CHO or
vice-versa. Because of its importance, we quote from this
article. The rationale for the study, according to the
authors is that:
"Compared with diets rich in saturated fats, low-fat, high-
carbohydrate diets are reported to reduce serum low-den-
sity lipoprotein (LDL) cholesterol levels. Recent studies,
however, suggest the high-carbohydrate diets may accen-
tuate hypertriglyceridemia, reduce serum high-density
lipoprotein (HDL) cholesterol concentration, and may
even worsen hyperglycemia and/or raise plasma insulin
levels."
In short, the question is whether high CHO diets worsen
MetS. The conclusions of the paper state:
"The study confirms that HC (high carbohydrate diets)
increase plasma TAG levels and increase VLDL-C concen-
trations in NIDDM patients. In this study the HC diet
raised fasting plasma triglyceride levels and VLDL-C con-
centrations by 24 % and 23 % respectively compared with
the HMUF diet. Furthermore, daylong levels of plasma
triglycerides were also elevated on the high-carbohydrate
diet. Consistent with the results of previous studies,
plasma levels of total cholesterol and LDL cholesterol
were not different on the two diets in this study. The
study, therefore substantiates the fact that high carbohy-
drate diets offer no advantage in lowering LDL levels in
NIDDM patients compared with high-fat diets that are
low in saturated fats."
The general case: substitution of fat for CHO improves 
MetS
The substitution of fat for CHO is, in fact, generally bene-
ficial for MetS. In a recent meta-analysis, Mensink, et al.
[62] showed the effect of substitution of different fat
sources or carbohydrate for the fat in the average US diet
at 10% of energy. The conclusion was that substitution of
carbohydrate had the most unfavorable response on the
total cholesterol to HDL ratio, significantly worse than
butter or palm oil (Figure 5).
Summary of review and hypothesis to this point
We have summarized work in the literature showing that
low CHO interventions improve the markers of MetS in
normal subjects, patients with MetS and diabetics. In
comparative studies, they are at least as effective as low fat
diets for weight loss and, tend to show better improve-
ment in the other markers of MetS. Isocaloric studies sim-
ilarly support the idea that the markers of MetS respond
preferentially to low CHO diets.
Effect of diet on plasma glucose Figure 4
Effect of diet on plasma glucose. Mean plasma glucose 
concentration before (triangles) and after 5 weeks on con-
trol diet (yellow circles: (CHO:fat:protein = 55:30:15)) or 5 
weeks on lower carbohydrate diet (blue circles: (20:50:30)). 
Meal points are Breakfast (B), lunch (L) and dinner(D) plus 2 
snacks (S1, S2). Data from reference [57].Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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The state of accepted scientific thinking for the world at
large is unknown but we have made the case that it is an
acknowledged principle that low CHO diets tend to
reduce TAG, raise HDL and improve glycemic control
whereas LF/high CHO diets tend to have the opposite
effect. Perhaps the strongest indication that such an idea
is generally accepted is the paper by Rock, et al [63] where
the effect of low fat diets in cancer patients was studied. To
demonstrate compliance with the low fat recommenda-
tions, the authors showed increased TAG and reduced
HDL levels. These effects were judged not significant
enough to cause a risk for CVD but demonstrate that low
fat (higher CHO) diets point in that direction.
We reiterate that this article is not meant to make recom-
mendations – for which many factors must be considered
– but rather to show the association between CHO restric-
tion and improvement in symptoms of MetS. Many low
fat interventions have successfully reduced LDL, an estab-
lished risk factor for CVD. If our hypothesis is correct,
however, these same interventions should worsen the fea-
tures of MetS. To some extent this is established from the
principles noted above, but we provide an example from
a well done experiment in the literature to support this
corollary. Finally, in considering the dialectic of treating
MetS with CHO restriction vs. high LDL, with low fat
diets, it is important to consider both individual variation
and the role of LDL particle size. We consider that last.
Studies of low-fat diets
The most salient feature of the obesity epidemic from the
standpoint of food consumption is the dramatic increase
in CHO intake and the reduction in fat intake (for men,
the absolute amount). To our knowledge, the decreased
fat intake has not been accompanied by reduction in the
incidence of CVD in unmedicated population. These data
suggest that low fat diet recommendations per se are not
likely to help MetS. If the fundamental idea proposed here
is correct, then experimental interventions targeting lower
fat that concomitantly raise CHO should, in fact, have a
deleterious effect on the markers of MetS. Again, one will
have to decide if the symptoms of MetS are more impor-
tant than LDL or total cholesterol which are typically
reduced on LF diets in the unmedicated population.
Delta-1 Study
The Delta-1 study is one of the very well done trials
involving a large number of participants [64]. The goal
was to determine "the effects of reducing total fat and sat-
urated fat" although this is slightly misleading in that only
saturated fat was reduced and any reduction in total fat
was a consequence of this. The randomized and balanced
diets that were compared all contained approximately 15
% of calories as protein. Other macronutrients were as
shown in Table 5. (Table 6) shows the outcomes for all
groups on lipids in the Delta-1 study. The results indicate
that LDL is significantly reduced although only SEM is
given so that it is not possible to know the range of
responses of subjects. As a group, however, there were
step-wise reductions in LDL and HDL going from the aver-
age American diet (AAD) to Step 1 to the low saturated fat
diet. There is, as well, a corresponding increase in TAG
and hence the TAG/HDL ratio. The authors concluded
that the reduction in LDL should be associated with 10%
to 20% reductions in cardiovascular disease in the popu-
lation. Other authors have argued, however, that the effect
of the 13% higher HDL seen on the AAD might be associ-
ated with a 36% reduction in the risk of death from coro-
nary disease or of myocardial infarction [65]. Again, the
purpose here is not to decide on the relative risk attached
to different markers but only to point out that the markers
for MetS provide another side to the story. An important
follow-up in the Delta study to determine HDL subpopu-
lations [66], showed that the more anti-atherogenic HDL2
particles were, in fact, decreased by reductions in saturated
fat.
The overall conclusion is that "dietary changes suggested
to be prudent for a large segment of the population will
primarily affect the concentrations of the most prominent
antiatherogenic HDL subpopulation. However, the simul-
taneous reduction in the atherogenic LDL subpopulation
will most likely offset any potential negative effect on car-
diovascular risk." As noted above, the decision as to "most
Changes in cholesterol/HDL for substitution for fat Figure 5
Changes in cholesterol/HDL for substitution for fat. 
Fat in the average American diet was substituted with the 
indicated substances at 10 % of energy. Data from reference 
[62].Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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likely" outcome must rest with individual patients and
physicians.
Role of individual responses and LDL heterogeneity
As noted in Garg's study, changes in LDL may not be as
reliable as changes in other markers. Volek, et al. for exam-
ple showed that whereas TAG was reduced in almost every
subject on a low CHO diet, responses in LDL were highly
variable [67]. The importance of LDL subpopulations has
recently been appreciated and, unlike total LDL, changes
in specific LDL particles show a consistent pattern with
respect to dietary change.
Greater atherogenic potential is associated with small,
dense LDL particles [68]. Krauss and coworkers have car-
ried out impressive work in defining the variability in dif-
ferent individuals. They identified a genetically influenced
pattern (B) in people whose plasma contains small LDL
particles. This subpopulation, typically 30 % of the Amer-
ican population, responded to low-fat diets by lowering
LDL but the pattern B persisted [69]. The remaining sub-
population with larger buoyant particles (pattern A)
responded to reduction in fat intake by a shift to the more
atherogenic pattern B. Thus, for most of the populations
studied, replacing dietary fat with CHO leads to a worsen-
ing of the LDL size distribution [70]. In a study described
in reference [70], similar effects were seen when protein
was substituted for carbohydrate without significant
change in the fat content or composition. As summarized
by Krauss, "This indicates that carbohydrate rather than
fat is a major dietary determinant of expression or pheno-
type B in susceptible individuals." Although probably a
semantic point, "susceptible" is redundant and describing
pattern A and B as phenotypes may not be precise: Krauss
has summarized how the relative amounts of CHO and
fat affect the prevalence of pattern B [71] and the conclu-
sion is that a strong relation exists between CHO intake
(ranging from 40 to 75%) and the prevalence of the pat-
tern B phenotype (Fig 6). In other words, there appears to
be a continuous variability in phenotype characterized by
sensitivity to CHO and everyone may be susceptible to
conversion to pattern B at some CHO/fat ratio. The
extrapolated line in Figure 6 suggests that a truly low CHO
diet might reduce the level of atherogenic subtype to zero.
Thus, whereas we have described the dialectic in practical
applications as balancing the improvement in MetS with
CHO restriction and the improvement in LDL from low-
fat diets, focusing on LDL may have some caveats. In gen-
eral, a growing body of work has shown improvement in
LDL pattern switching from high CHO to low CHO diets
[42,43,72-75].
The pattern B phenotype rarely occurs in isolation and,
our major concern here is that it is metabolically linked to
and co-expressed with other characteristics of MetS, par-
ticularly elevated TAG and low HDL. Krauss and col-
leagues reported that switching from a low CHO/high-fat
diet (46% fat) to a high CHO/low-fat diet (26% fat)
resulted in lowering of LDL, but also a worsening of TAG
and HDL when switching to the low fat diet [69]. In men
that were pattern A at a fat intake of 20 to 24%, a further
reduction in dietary fat to 10% and CHO to 76% of energy
resulted in conversion to B, with continued worsening of
TAG and HDL, and no additional LDL-lowering [76].
Table 6: 
Ave American Diet vs. Step 1 Ave American Diet vs. Low Sat Fat
Ginsberg, et al.,1998 reference [64] AAD Step 1 delta % change pre post delta % change
Total cholesterol 202.1 191 -11.1 -5.5 202.1 183.4 -18.7 -9.3
LDL 131.4 122.2 -9.2 -7.0 131.4 116.9 -14.5 -11.0
TAG (mmol/l) antiln (log) 85.1 92.4 7.3 8.6 85.1 93 7.9 9.3
HDL (mmol/l) 52.2 48.5 -3.7 -7.1 52.2 46.2 -6.0 -11.5
Total/HDL 4.1 4.16 0.1 2.2 4.1 4.21 0.1 3.4
TAG/HDL (arbitrary units) 1.6 1.9 0.3 16.9 1.6 2.0 0.4 23.5
Table 5: Macronutrient composition of diets in the Delta-1 study. Data from reference [64].
Diet CHO (%) total fat (%) SFA (%) MUFA (%) PUFA (%)
Average American diet (AAD) 48 34 15 13 7
Step 1 55 29 9 13 7
Low Saturated Fat 59 25 6 12 7Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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The TAG/HDL connection
In the search for markers for both insulin resistance and
predisposition to CVD, recent research has focused on the
value of the ratio of TAG:HDL. McLaughlin, et al. [8] have
shown a correlation between insulin resistance as meas-
ured by steady-state glucose levels after infusion of glu-
cose, insulin and octreotide (to suppress endogenous
insulin secretion). The conclusions of their study were
that TAG and HDL were independently related to insulin
resistance and the TAG/HDL ratio was the best predictor
of insulin resistance. Of importance here is that the results
showed that this ratio is comparable to the ATP III criteria
for MetS in predicting insulin resistance and "even better
in prediction the LDL phenotype B in two separate popu-
lations who were on different diets." This is, in fact, only
the most recent of several studies (references in [8]) that
have shown a correlation between TAG/HDL and insulin
resistance and CVD risk as measured by LDL particle size.
Table 2-4 as well as Figures 2 and 5 indicate that low CHO
diets reliably reduce this marker. Inability to recognize
this is again due to the separate conditions in which they
are measured and the continued emphasis on reducing
dietary fat above all else.
McLaughlin's analysis [8] identified a TAG/HDL ratio of ≥
3.5 as a cutoff for identifying the insulin-resistant patient
most at risk for CVD. It is of interest that in Foster's study
[45] described above (Table 3; Figure 1), the average
beginning values were 4.6 and 4.3 in the low CHO and
low-fat arms, respectively, substantially above this cutoff
value. After six months, the low CHO arm had reduced
this marker to 3.7 while the LF group showed little change
at 4.2. Similarly, in the Delta-1 study, neither the Step 1
diet nor the low fat diet were able to improve the TAG/
HDL ratio which was above the threshold value of 3.5
(Table 6)).
Mechanism
A recent review by Ginsberg [77] has provided an excellent
description of the possible mechanisms and central role
of insulin resistance in mediating the dyslipidemia of
MetS. In combination with a proposal by Volek [13] on
the mechanism for the reversal of this process, a reasona-
ble understanding of the connection between MetS and
CHO restriction is possible.
A primary target of insulin is hormone-sensitive lipase.
Adipocyte insulin resistance, plausibly a down regulation
of insulin response due to continued stimulation (from
higher dietary CHO), leads to increased lipolysis [78,79].
This will lead to greater delivery of fatty acids and an
increase in hepatic esterification, and subsequent over
production of VLDL, particularly the TAG-rich VLDL1. In
combination with impaired plasma TAG clearance, a con-
stant state of hypertriglyceridemia in the postabsorptive
and postprandial period occurs. This leads to the
exchange of TAG in VLDL for cholesteryl ester in LDL. The
resulting TAG-rich LDL particle is a preferred substrate for
hepatic lipase and lipoprotein lipase and thereby for gen-
eration of small, dense LDL. A similar neutral lipid
exchange likely occurs with HDL whereby TAG-rich HDL
is hydrolyzed by lipoprotein lipase resulting in the gener-
ation of smaller HDL particles that are rapidly removed
from the circulation. In this way, elevated TAG resulting
from disruption in insulin function, plays a central role in
regulating the atherogenic dyslipidemia of MetS.
As noted above, Volek, et al. [13] have reviewed many
studies showing that CHO restriction results in significant
reductions in postprandial lipemia, and beneficial effects
on HDL and intravascular processing of lipoproteins. A
key component is what might be called the fatty acid par-
adox. Whereas insulin resistance is frequently character-
ized by high fatty acid levels, CHO restriction can improve
insulin resistance while raising fatty acids. The latter effect
is presumed to be due to lower insulin levels and disinhi-
bition of hormone sensitive lipase. This is accompanied
by enhanced cellular fatty acid uptake, mitochondrial
transport and increased oxidation. The bias toward fat oxi-
dation over storage reduces hepatic TAG and reduces syn-
thesis and secretion of VLDL.
Discussion
A joint position statement by several organizations rec-
ommended "current dietary guidelines from the ADA,
Prevalence of pattern B phenotype as a function of the per- centage dietary CHO in men Figure 6
Prevalence of pattern B phenotype as a function of the per-
centage dietary CHO in men. Data from reference [71].Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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AHA and the NCEP-ATP III.... These recommendations
may require modification, however, as new information is
generated from additional diet intervention studies [80]."
Rather than additional studies, however, we provide new
information from an evaluation of papers already in the
literature that may provide a basis for modification. Data
compiled in Figures 2, 3, 4 show that low CHO diets
improve the symptoms of MetS as defined by five com-
mon criteria. We propose that in addition to potential
value as therapy, the response to CHO restriction might
be considered an operational definition of MetS. Beyond
formal categorizing, the idea is consistent with the gener-
ally held belief that MetS is intimately involved with some
form of insulin resistance. (The importance of other fac-
tors such as inflammation are not mutually exclusive).
Cornier et al. showed differential benefit of low CHO vs.
low fat diets for people with or without insulin resistance
[51]; this study might be thought of as a model for future
work to follow this line of thinking. We emphasize that
our main point is that an intimate connection between
CHO restriction and the complex of symptoms of MetS is
seen in the literature of both low CHO studies and low fat
(higher CHO) studies. Individual judgment as to the
importance of MetS compared to other specific factors or
more global assessments such as the Framingham criteria
will determine how use is made of this connection. We do
believe, however, that ignoring studies on CHO restric-
tion would be unscientific and unproductive.
How low is low carbohydrate?
Goneril. What need you five-and-twenty, ten, or five...?
Regan. What need one?
- William Shakespeare, King Lear.
The data summarized here suggest that some degree of
CHO restriction would provide a first line of attack against
the symptoms of MetS. The principle of CHO restriction is
that by keeping insulin low, metabolism is biased towards
lipid oxidation rather than storage, or the effects of fatty
acids on peripheral tissues. Most studies that reported del-
eterious effects of saturated fat have been carried out in
the presence of high CHO and there is a real question
whether such effects carry over into hypocaloric condi-
tions or those where insulin is better controlled
[28,60,81,82].
In general, whereas current thinking in MetS emphasizes
the consequences of insulin resistance, we feel that the
role of CHO-induced hyperinsulinemia as a causative fac-
tor in generating the initial insulin resistance, dyslipi-
demia or obesity has been under-appreciated. In any case,
there are now many ways to implement CHO restriction
ranging from ketogenic diets (less than 50 g/d) to diets
based on glycemic index, an indirect method of reducing
insulin excursions. The question is how low is low? It is
clear that 40% CHO is better than 55% for MetS and there
has been some reluctance to go lower even though the
studies that have done so show continued improvement.
Perusal of Table 2-4 suggests that the lower, the better.
Insofar as pattern B is associated with insulin resistance
and MetS, examination of Figure 4 supports this idea. The
barriers to exploring lower CHO diets appears to be con-
tinued emphasis on low fat intake although it has been
known since Keys's Seven Country study that total fat in
the diet does not correlate with cardiovascular risk [38]. At
least as indicated in its popular diet book, the No-Fad Diet
[83], the American Heart Association has removed its lim-
itation on total fat which should open the door to more
flexible diet interventions. Since many studies have
shown that there is frequently a spontaneous reduction in
total caloric intake in very low CHO diets and that CHO
removed is not replaced by fat or protein, very low CHO
now appears as a far more prudent choice than judged in
the past.
Is this new?
The phenomenon of CHO-induced hypertriglyceridemia
is long established [84-88]. In addition, low fat diets are
known to reduce, not only LDL, but also HDL levels. For
example, the 2004 recommendations of the American
Diabetic Association (ADA) state that "Low-saturated fat
(i.e., 10% of energy) high carbohydrate diets increase post-
prandial levels of plasma glucose, insulin, triglycerides and, in
some studies, decrease plasma HDL cholesterol when com-
pared in metabolic studies to isocaloric high monoun-
saturated fat diets." This is our conclusion (our italics). We
think the ADA statement could have been more clearly
worded: "Substitution of CHO for monounsaturated fat
"increase(s) postprandial levels of plasma glucose, insu-
lin..." or could have been more comprehensive: "substitu-
tion of CHO or protein for fat increases..." In other words,
it has been known for some time that low fat reduces HDL
as well as LDL concentrations as described clearly in the
Delta-1 study. Again, Rock's study that used the increase
in TAG and decrease in HDL as a marker for compliance
to a low fat diet supports the idea as an accepted principle.
In combination with the experimentally observed and
intuitively obvious reduction in fasting blood glucose and
insulin, our proposal for the importance of CHO replace-
ment in the diet hardly seems new. Yet such an idea, to
our knowledge has never been made explicit. The primacy
of the low fat paradigm in traditional thinking may have
played a role in ignoring this obvious correlation. How-
ever, we have, in various places, presented or summarized
evidence that low CHO diets have a beneficial effect on
MetS [13,16] but the tight connection proposed here con-
ceptually eluded us. Having raised the question, however,Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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it is now clear that it is perfectly consistent with estab-
lished knowledge.
Is MetS useful?
The intricacies of the debate among official agencies on
the clinical importance of MetS [9] are beyond the scope
of this article. As a first order approximation, however, we
are inclined to follow Reaven's strategy in the Point/
Counterpoint paper [10,89] for assessing the need for the
concept of MetS. He describes a patient with a BMI of 27.8
kg/m2 who would not conform to the WHO definition of
MetS because of acceptable values of glucose, TAG and an
HDL level of 37 mg/dL and he points out that if the HDL
level fell to 33 mg/dL such a patent would fit a new criteria
but would not sensibly be treated in a different way.
Under the approach considered here, the patient with the
higher HDL would be presented with a number of options
for weight loss whereas the patient with lower HDL might
reasonably be counseled to CHO restriction as a first strat-
egy. We therefore think that MetS or some combination of
markers by any other name would have much more viril-
ity than the description of MetS as Methuselah in his
amusing Counterpoint [87]. We also side with the "Pro"
position on the value for basic research. Reaven raises the
critical question: "How can there be a common etiology
for a diagnostic category based on satisfying 3 of 5 arbi-
trarily defined criteria when any combination of the 3 will
define the same phenotype as any other trio of abnormal-
ities.?" A plausible answer to this question is that if all the
markers in MetS are related to hyperinsulinemia and/or
insulin resistance, then the relative Km's for insulin for the
different target proteins and different tissues are likely to
lead to a variable time course for specific individuals and
markers are likely to exceed cutoff at different times for
each patient. Appearance of one marker may then be
indicative of other still silent conditions.
Recommendations for the American population
The data summarized here suggest that there is value in
the definition of MetS and that a nutritional strategy
based on CHO restriction might sensibly be the "default"
diet, the first to be tried, for patients with MetS. In the case
of normal weight individuals with MetS, CHO restriction
may be the only effective non-pharmacological approach
for treating the diversity of symptoms. The choice of any
intervention, however, depends on individual assessment
of the relative importance of different risk factors and our
goal here is the establishment of the close link between
CHO restriction and MetS rather than any recommenda-
tion.
The recent AHA/NHLBI Scientific Statement on Metabolic
Syndrome [90,91] as well as the ATP III emphasize as the
primary target, LDL, a marker that is not considered a fea-
ture of MetS and that may not even be high in many
patients with MetS. Whereas nutritional recommenda-
tions are quite general (reduce weight, increase exercise),
these reports emphasize a low fat diet (although limiting
simple sugars). We think this is inconsistent and we have
made the case that a low fat diet, if high in carbohydrate,
seems to be widely accepted as raising TAG, lowering HDL
and worsening glycemic control, seemingly the wrong
thing for MetS. We also disagree with the assertion in the
AHA/NHLBI statement that most low CHO diets are high
in saturated fat. This statement is undocumented and, as
noted in the introduction, essentially equates all reduced
carbohydrate approaches and does not seem to distin-
guish between total and saturated fat. Even if it were true
the statement avoids the question of the effect of saturated
fat in the presence of low CHO or hypocaloric diets
[60,81,82,92]. In practical terms, a recommendation to
reduce saturated fat on low CHO diets might be more
helpful than blanket prohibition. In addition, the AHA/
NHLBI report [90] presents the rationale for low CHO as
the effect on appetite. Whereas this may be a component,
it has been stated many times, and is part of basic bio-
chemical education [16,93-96], that the rationale of CHO
restriction is the control of metabolism by insulin regula-
tion. The effects described above clearly support this.
Although we think that, within the framework of MetS,
some recommendations can be made, in the end we are
probably in agreement with Reaven's judgment that
"What is required is less advice and more information
[54]."
Questions raised
The data summarized here leave little room for doubt that
the generally accepted deterioration in HDL and TAG lev-
els with low fat diets and the established improvement in
glycemic control with CHO restriction are part of a more
general picture. The hypothesis that response to CHO
restriction (because of the effect on insulin) is the defining
feature of MetS is the proposed generalization. This idea
raises several questions.
Is there a threshold level of CHO restriction that is neces-
sary to elicit improvements in MetS? What is the effect of
replacing the calories lost from CHO with protein or with
fat, and in what proportion? How does this compare to
not replacing them at all?
Does excessive CHO consumption cause MetS in suscepti-
ble individuals?
What is the relative risk in addressing MetS with CHO
restriction compared to low fat diets for reduction in LDL?
That is, what is the relative risk of high LDL vs. the symp-
toms that comprise MetS?Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
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What is the role of genotype in determining the response
to CHO restriction?
Summary
Five symptoms common to most definitions of MetS are
those that are reliably improved by CHO restriction. Car-
bohydrate restriction is one strategy for weight loss but, in
addition, improves glycemic control, insulin levels, TAG
and HDL levels even in the absence of weight loss. We sug-
gest that response to CHO restriction may, in fact, be an
operational definition of MetS. Its underlying basis would
rest on the idea that the features of MetS are associated
with a disruption in insulin metabolism which is strongly
influenced by dietary CHO. The extent to which this defi-
nition is useful may depend on its application by individ-
ual practitioners. Experimental studies that follow its lead
or conversely disprove its fundamental premise should
advance our understanding of obesity, diabetes and CVD.
Dismissing CHO restriction without evidence, or express-
ing "concerns" rather than offering data will probably be
less productive.
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Note
Table 2 - Effect of carbohydrate restriction on markers
for Metabolic Syndrome (See Table 2)
Data shown in bold indicate improvement in marker,
plain, worsening. References:1. [97]; 2. [24]; 3. [98]; 4.
[99]; 5. [100]; 6. [101]; 7. [42]; 8. [102]; 9. [103]; 10.
[104]; 11. [74]; 12. [105]; 13. [23].
Table 3 - Effect of carbohydrate restriction on markers
for Metabolic Syndrome under conditions of constant
body mass (See Table 3)
Data shown in bold indicate low CHO shows greater
improvement in markers for MetS than LF; plain, LF is bet-
ter. Table reference 3 shows the ratio of low CHO to LF.
References: 1. [42]; 2. [43]; 3. [44].
Table 4 - Comparison of low CHO vs. LF diets on mark-
ers for Metabolic Syndrome (See Table 4)
Data shown in bold indicate low CHO (or mod-PROT)
shows greater improvement in marker than LF; plain, LF is
better. Experiment in reference [106] was carried out for a
longer time period but diets became very similar. Refer-
ences:1. [107]; 2. [113]; 3. [46]; 4. [45]; 5. [108]; 6. [72];
7. [109]; 8. [110]; 9. [111]; 10. [112]; 11. [73]; 12. [75];
13. [59]; 14. [106].
Table 6 - Outcomes of the Delta-1 study (See Table 6)
Data from reference [64]. bold indicates improvement in
the parameter from Step 1 or low Saturated Fat diet com-
pared to AAD; plain indicates worsening of parameter
compared to AAD.
References
1. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome.
Lancet 2005, 365(9468):1415-1428.
2. Grundy SM, Brewer HBJ, Cleeman JI, Smith SCJ, Lenfant C: Defini-
tion of metabolic syndrome: Report of the National Heart,
Lung, and Blood Institute/American Heart Association con-
ference on scientific issues related to definition.  Circulation
2004, 109(3):433-438.
3. Grundy SM, Hansen B, Smith SCJ, Cleeman JI, Kahn RA: Clinical
management of metabolic syndrome: report of the Ameri-
can Heart Association/National Heart, Lung, and Blood
Institute/American Diabetes Association conference on sci-
entific issues related to management.  Arterioscler Thromb Vasc
Biol 2004, 24(2):e19-24.
4. Tonkin A: The metabolic syndrome -- a growing problem.
European Heart Journal Supplements 2004, 6:A37-A42.
5. Aude YW, Mego P, Mehta JL: Metabolic syndrome: dietary inter-
ventions.  Curr Opin Cardiol 2004, 19(5):473-479.
6. Hanley AJ, Wagenknecht LE, D'Agostino RBJ, Zinman B, Haffner SM:
Identification of subjects with insulin resistance and beta-cell
dysfunction using alternative definitions of the metabolic
syndrome.  Diabetes 2003, 52(11):2740-2747.
7. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National
Cholesterol Education Program versus World Health
Organization metabolic syndrome in relation to all-cause
and cardiovascular mortality in the San Antonio Heart
Study.  Circulation 2004, 110(10):1251-1257.
8. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D,
Simon J, Krauss RM: Is there a simple way to identify insulin-
resistant individuals at increased risk of cardiovascular dis-
ease?  Am J Cardiol 2005, 96(3):399-404.
9. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome:
time for a critical appraisal: joint statement from the Amer-
ican Diabetes Association and the European Association for
the Study of Diabetes.  Diabetes Care 2005, 28(9):2289-2304.
10. Grundy SM: Point: the metabolic syndrome still lives.  Clin Chem
2005, 51(8):1352-1354.
11. Reaven GM: The metabolic syndrome: requiescat in pace.  Clin
Chem 2005, 51(6):931-938.
12. Arora SK, McFarlane SI: The case for low carbohydrate diets in
diabetes management.  Nutr Metab (Lond) 2005, 2:16.
13. Volek JS, Sharman MJ, Forsythe CE: Modification of lipoproteins
by very low-carbohydrate diets.  J Nutr 2005, 135(6):1339-1342.
14. Third Report of the National Cholesterol Education Pro-
gram (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) final report.  Circulation 2002,
106(25):3143-3421.
15. Ashen MD, Blumenthal RS: Clinical practice. Low HDL choles-
terol levels.  N Engl J Med 2005, 353(12):1252-1260.
16. Feinman RD, Makowske M: Metabolic Syndrome and Low-Car-
bohydrate Ketogenic Diets in the Medical School Biochem-
istry Curriculum.  Metabolic Syndrome and Related Disorders 2003,
1:189-198.Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
Page 15 of 17
(page number not for citation purposes)
17. Westman EC, Yancy Jr. WS, Haub MD, Volek JS: Insulin Resistance
from a Low-Carbohydrate, High Fat Diet Perspective.  Meta-
bolic Syndrome and Related Disorders 2005, 3:3-7.
18. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabol-
ically obese, normal-weight individual revisited.  Diabetes
1998, 47(5):699-713.
19. Willet W: Increasing prevalence of overweight among US
adults. The National Health and Nutrition Examination Sur-
veys, 1960 to 1991.  JAMA  1994, 272:205-211.
20. Poppitt SD, Keogh GF, Prentice AM, Williams DE, Sonnemans HM,
Valk EE, Robinson E, Wareham NJ: Long-term effects of ad libi-
tum low-fat, high-carbohydrate diets on body weight and
serum lipids in overweight subjects with metabolic syn-
drome.  Am J Clin Nutr 2002, 75(1):11-20.
21. Enns CK, Goldman JD, Cook A: Trends in Food and Nutrient
Intakes by Adults: NFCS 1977-78, CSFII 1989-91, and CSFII
1994-95.  Family Economics and Nutrition Review 1997, 10:2-15.
22. Kennedy ET, Bowman SA, Powell R: Dietary-fat intake in the US
population.  J Am Coll Nutr 1999, 18(3):207-212.
23. Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP: Effect of a low-
carbohydrate diet on appetite, blood glucose levels, and
insulin resistance in obese patients with type 2 diabetes.  Ann
Intern Med 2005, 142(6):403-411.
24. Larosa JC, Fry AG, Muesing R, Rosing DR: Effects of high-protein,
low-carbohydrate dieting on plasma lipoproteins and body
weight.  J Am Diet Assoc 1980, 77(3):264-270.
25. Miller BV, Bertino J, Reed TG, Burrington C, Davidson LK, Green A,
Gartung A, Nafziger A: An Evaluation of the Atkins' Diet.  Meta-
bolic Syndrome and Related Disorders 2003, 1:299-309.
26. Bray GA: The epidemic of obesity and changes in food intake:
the Fluoride Hypothesis.  Physiol Behav 2004, 82(1):115-121.
27. Martin WF, Armstrong LE, Rodriguez NR: Dietary Protein Intake
and Renal Function.  Nutr Metab (Lond) 2005, 2(1):25.
28. Van der Auwera I, Wera S, Van Leuven F, Henderson ST: A
ketogenic diet reduces amyloid beta 40 and 42 in a mouse
model of Alzheimer's disease.  Nutr Metab (Lond) 2005.
29. Veech RL: The therapeutic implications of ketone bodies: the
effects of ketone bodies in pathological conditions: ketosis,
ketogenic diet, redox states, insulin resistance, and mito-
chondrial metabolism.  Prostaglandins Leukot Essent Fatty Acids
2004, 70(3):309-319.
30. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GFJ: Ketone
bodies, potential therapeutic uses.  IUBMB Life 2001,
51(4):241-247.
31. Brand-Miller JC: Glycemic index in relation to coronary dis-
ease.  Asia Pac J Clin Nutr 2004, 13(Suppl):S3.
32. Brand-Miller JC: Postprandial glycemia, glycemic index, and
the prevention of type 2 diabetes.  Am J Clin Nutr 2004,
80(2):243-244.
33. Atkins RC: Dr. Atkins' New Diet Revolution.  New York , Avon
Books; 2002. 
34. Agatston A: The South Beach Diet.  New York , Random House;
2003. 
35. Eades MR, Eades MD: Protein Power.  New York , Bantam Books;
1996. 
36. Hu FB, Manson JE, Willett WC: Types of dietary fat and risk of
coronary heart disease: a critical review.  J Am Coll Nutr 2001,
20(1):5-19.
37. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA,
Hennekens CH, Willett WC: Dietary fat intake and the risk of
coronary heart disease in women.  N Engl J Med 1997,
337(21):1491-1499.
38. Keys A: Coronary heart disease in seven countries.  1970, 41
(Suppl):1-211.
39. Feinman RD, Fine EJ: Thermodynamics and Metabolic Advan-
tage of Weight Loss Diets.  Metabolic Syndrome and Related Disor-
ders 2003, 1:209-219.
40. Volek JS, Westman EC: Very-low-carbohydrate weight-loss
diets revisited.  Cleve Clin J Med 2002, 69(11):849, 853, 856-8 pas-
sim.
41. Westman EC, Mavropoulos J, Yancy WS, Volek JS: A Review of
Low-carbohydrate Ketogenic Diets.  Curr Atheroscler Rep 2003,
5(6):476-483.
42. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett
TP, Volek JS: A ketogenic diet favorably affects serum biomar-
kers for cardiovascular disease in normal-weight men.  J Nutr
2002, 132(7):1879-1885.
43. Volek JS, Sharman MJ, Gomez AL, Scheett TP, Kraemer WJ: An Iso-
energetic Very Low-Carbohydrate Diet Is Associated With
Improved Serum High-Density Lipoprotein Cholesterol
(HDL-C), Total Cholesterol to HDL-C Ratio, Triacylglycer-
ols, and Postprandial Lipemic Responses Compared to a
Low-Fat Diet in Normal Weight, Normolipidemic Women.
J Nutr 2003, 133(9):2756-2761.
44. Allick G, Bisschop PH, Ackermans MT, Endert E, Meijer AJ, Kuipers
F, Sauerwein HP, Romijn JA: A low-carbohydrate/high-fat diet
improves glucoregulation in type 2 diabetes mellitus by
reducing postabsorptive glycogenolysis.  J Clin Endocrinol Metab
2004, 89(12):6193-6197.
45. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS,
Szapary PO, Rader DJ, Edman JS, Klein S: A randomized trial of a
low-carbohydrate diet for obesity.  N Engl J Med 2003,
348(21):2082-2090.
46. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J,
Williams T, Williams M, Gracely EJ, Stern L: A low-carbohydrate
as compared with a low-fat diet in severe obesity.  N Engl J Med
2003, 348(21):2074-2081.
47. Feinman RD, Fine EJ: "A Calorie is a calorie" violates the second
law of thermodynamics.  Nutrition Journal 2004, 3(9):.
48. Feinman RD, Fine EJ: Whatever happened to the second law of
thermodynamics?  Am J Clin Nutr 2004, 80(5):1445-6; author reply
1446.
49. Fine EJ, Feinman RD: Thermodynamics of weight loss diets.
Nutr Metab (Lond) 2004, 1(1):15.
50. Bray GA, Champagne CM: Beyond energy balance: there is
more to obesity than kilocalories.  J Am Diet Assoc 2005, 105(5
Suppl 1):S17-23.
51. Cornier MA, Donahoo WT, Pereira R, Gurevich I, Westergren R,
Enerback S, Eckel PJ, Goalstone ML, Hill JO, Eckel RH, Draznin B:
Insulin sensitivity determines the effectiveness of dietary
macronutrient composition on weight loss in obese women.
Obes Res 2005, 13(4):703-709.
52. Golay A, Eigenheer C, Morel Y, Kujawski P, Lehmann T, de Tonnac
N: Weight-loss with low or high carbohydrate diet?  Int J Obes
Relat Metab Disord 1996, 20(12):1067-1072.
53. Poe EA: The Purloined Letter.  http://xroadsvirginiaedu/~HYPER/
POE/purloinehtml 1845.
54. Reaven GM: Effect of dietary carbohydrate on the metabolism
of patients with non-insulin dependent diabetes mellitus.
Nutr Rev 1986, 44(2):65-73.
55. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H: An increase
in dietary protein improves the blood glucose response in
persons with type 2 diabetes.  Am J Clin Nutr 2003, 78(4):734-741.
56. Nuttall FQ, Gannon MC: Metabolic response of people with
type 2 diabetes to a high protein diet.  Nutr Metab (Lond) 2004,
1(1):6.
57. Gannon MC, Nuttall FQ: Effect of a high-protein, low-carbohy-
drate diet on blood glucose control in people with type 2 dia-
betes.  Diabetes 2004, 53(9):2375-2382.
58. Ludwig DS, Jenkins DJ: Carbohydrates and the postprandial
state: have our cake and eat it too?  Am J Clin Nutr 2004,
80(4):797-798.
59. McAuley KA, Hopkins CM, Smith KJ, McLay RT, Williams SM, Taylor
RW, Mann JI: Comparison of high-fat and high-protein diets
with a high-carbohydrate diet in insulin-resistant obese
women.  Diabetologia 2005, 48(1):8-16.
60. Feinman R: When is a high fat diet not a high fat diet?  Nutrition
& Metabolism 2005, 2(27):.
61. Garg A, Bantle JP, Henry RR, Coulston AM, Griver KA, Raatz SK,
Brinkley L, Chen YD, Grundy SM, Huet BA, et al.: Effects of varying
carbohydrate content of diet in patients with non-insulin-
dependent diabetes mellitus.  Jama 1994, 271(18):1421-1428.
62. Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary
fatty acids and carbohydrates on the ratio of serum total to
HDL cholesterol and on serum lipids and apolipoproteins: a
meta-analysis of 60 controlled trials.  Am J Clin Nutr 2003,
77(5):1146-1155.
63. Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman VA, Jones
L, Natarajan L, Pierce JP, Chang RJ, Witztum JL: Plasma triacylglyc-
erol and HDL cholesterol concentrations confirm self-Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
Page 16 of 17
(page number not for citation purposes)
reported changes in carbohydrate and fat intakes in women
in a diet intervention trial.  J Nutr 2004, 134(2):342-347.
64. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre
M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart
P, Phillips K, Anderson N: Effects of reducing dietary saturated
fatty acids on plasma lipids and lipoproteins in healthy sub-
jects: the DELTA Study, protocol 1.  Arterioscler Thromb Vasc Biol
1998, 18(3):441-449.
65. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA: High-
density lipoprotein cholesterol and coronary heart disease in
hypercholesterolemic men: the Lipid Research Clinics Coro-
nary Primary Prevention Trial.  Circulation 1986, 74:1217-1225.
66. Berglund L, Oliver EH, Fontanez N, Holleran S, Matthews K, Roheim
PS, Ginsberg HN, Ramakrishnan R, Lefevre M: HDL-subpopulation
patterns in response to reductions in dietary total and satu-
rated fat intakes in healthy subjects.  Am J Clin Nutr 1999,
70(6):992-1000.
67. Volek JS, Sharman MJ: Cardiovascular and hormonal aspects of
very-low-carbohydrate ketogenic diets.  Obes Res 2004, 12
Suppl 2:115S-23S.
68. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien
PJ, Despres JP: Small, dense low-density lipoprotein particles
as a predictor of the risk of ischemic heart disease in men.
Prospective results from the Quebec Cardiovascular Study.
Circulation 1997, 95(1):69-75.
69. Dreon DM, Fernstrom HA, Miller B, Krauss RM: Low-density lipo-
protein subclass patterns and lipoprotein response to a
reduced-fat diet in men.  Faseb J 1994, 8(1):121-126.
70. Krauss RM: Dietary and Genetic Probes of Atherogenic Dysl-
ipidemia.  Arterioscler Thromb Vasc Biol 2005.
71. Krauss RM: Atherogenic lipoprotein phenotype and diet-gene
interactions.  J Nutr 2001, 131(2):340S-3S.
72. Sharman MJ, Gomez AL, Kraemer WJ, Volek JS: Very low-carbohy-
drate and low-fat diets affect fasting lipids and postprandial
lipemia differently in overweight men.  J Nutr 2004,
134(4):880-885.
73. Aude YW, Agatston AS, Lopez-Jimenez F, Lieberman EH, Marie A,
Hansen M, Rojas G, Lamas GA, Hennekens CH: The national cho-
lesterol education program diet vs a diet lower in carbohy-
drates and higher in protein and monounsaturated fat: a
randomized trial.  Arch Intern Med 2004, 164(19):2141-2146.
74. Hays JH, DiSabatino A, Gorman RT, Vincent S, Stillabower ME: Effect
of a high saturated fat and no-starch diet on serum lipid sub-
fractions in patients with documented atherosclerotic cardi-
ovascular disease.  Mayo Clin Proc 2003, 78(11):1331-1336.
75. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA,
McGrory J, Gracely EJ, Rader DJ, Samaha FF: A randomized study
comparing the effects of a low-carbohydrate diet and a con-
ventional diet on lipoprotein subfractions and C-reactive
protein levels in patients with severe obesity.  Am J Med 2004,
117(6):398-405.
76. Dreon DM, Fernstrom HA, Williams PT, Krauss RM: A very low-fat
diet is not associated with improved lipoprotein profiles in
men with a predominance of large, low-density lipoproteins.
Am J Clin Nutr 1999, 69(3):411-418.
77. Ginsberg HN, Zhang YL, Hernandez-Ono A: Regulation of plasma
triglycerides in insulin resistance and diabetes.  Arch Med Res
2005, 36(3):232-240.
78. Boden G, Shulman GI: Free fatty acids in obesity and type 2 dia-
betes: defining their role in the development of insulin resist-
ance and beta-cell dysfunction.  Eur J Clin Invest 2002, 32 Suppl
3:14-23.
79. Zammit VA: Insulin stimulation of hepatic triacylglycerol
secretion in the insulin-replete state: implications for the eti-
ology of peripheral insulin resistance.  Ann N Y Acad Sci 2002,
967:52-65.
80. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y,
Eckel RH: Clinical implications of obesity with specific focus
on cardiovascular disease: a statement for professionals
from the American Heart Association Council on Nutrition,
Physical Activity, and Metabolism: endorsed by the Ameri-
can College of Cardiology Foundation.  Circulation 2004,
110(18):2952-2967.
81. Mozaffarian D, Rimm EB, Herrington DM: Dietary fats, carbohy-
drate, and progression of coronary atherosclerosis in post-
menopausal women.  Am J Clin Nutr 2004, 80(5):1175-1184.
82. Volek JS, Forsythe CE: The case for not restricting saturated fat
on a low carbohydrate diet.  Nutr Metab (Lond) 2005, 2:21.
83. American Heart Association: No-Fad Diet.  A Personal Plan fo
Healthy Weight Loss.  New York , Clarkson Potter; 2005. 
84. Hellerstein MK: Carbohydrate-induced hypertriglyceridemia:
modifying factors and implications for cardiovascular risk.
Curr Opin Lipidol 2002, 13(1):33-40.
85. Hudgins LC: Effect of high-carbohydrate feeding on triglycer-
ide and saturated fatty acid synthesis.  Proc Soc Exp Biol Med
2000, 225(3):178-183.
86. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J:
Human fatty acid synthesis is stimulated by a eucaloric low
fat, high carbohydrate diet.  J Clin Invest 1996, 97(9):2081-2091.
87. Parks EJ, Hellerstein MK: Carbohydrate-induced hypertriacylg-
lycerolemia: historical perspective and review of biological
mechanisms.  Am J Clin Nutr 2000, 71(2):412-433.
88. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK:
Effects of a low-fat, high-carbohydrate diet on VLDL-triglyc-
eride assembly, production, and clearance.  J Clin Invest 1999,
104(8):1087-1096.
89. Reaven G: Counterpoint: just being alive is not good enough.
Clin Chem 2005, 51(8):1354-1357.
90. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin
BA, Gordon DJ, Krauss RM, Savage PJ, Smith SCJ, Spertus JA, Costa
F: Diagnosis and Management of the Metabolic Syndrome.
An American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement.  Circulation 2005.
91. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin
BA, Gordon DJ, Krauss RM, Savage PJ, Smith SCJ, Spertus JA, Costa
F: Diagnosis and Management of the Metabolic Syndrome.
An American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement. Executive Summary.
Circulation 2005.
92. Knopp RH, Retzlaff BM: Saturated fat prevents coronary artery
disease? An American paradox.  Am J Clin Nutr 2004,
80(5):1102-1103.
93. Pogozelski W, Arpaia N, Priore S: The Metabolic Effects of Low-
carbohydrate Diets and Incorporation into a Biochemistry
Course.  Biochemistry and Molecular Biology Education 2005,
33:91-100.
94. Harris RA, Crabb DW: Chapter 22. Metabolic Interrelation-
ships.  In Textbook of Biochemistry With Clinical Correlations Sixth edi-
tion. Edited by: Devlin TM. New York , John Wiley & Sons, Inc.; 2006. 
95. Makowske M, Feinman RD: Nutrition education: a question-
naire for assessment and teaching.  Nutr J 2005, 4(1):2.
96. Smith C, Marks AD, Lieberman M: Basic Medical Biochemistry: A
Clinical Approach.  2nd edition. Philadelphia , Lippincott Williams
& Wilkins; 2005. 
97. Rickman F, Mitchell N, Dingman J, Dalen JE: Changes in serum cho-
lesterol during the Stillman diet.  Jama 1974, 228(1):54-58.
98. Phinney SD, Horton ES, Sims EA, Hanson JS, Danforth EJ, LaGrange
BM: Capacity for moderate exercise in obese subjects after
adaptation to a hypocaloric, ketogenic diet.  J Clin Invest 1980,
66(5):1152-1161.
99. Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL: The
human metabolic response to chronic ketosis without
caloric restriction: preservation of submaximal exercise
capability with reduced carbohydrate oxidation.  Metabolism
1983, 32(8):769-776.
100. Newbold HL: Reducing the serum cholesterol level with a diet
high in animal fat.  South Med J 1988, 81(1):61-63.
101. Volek JS, Gomez AL, Kraemer WJ: Fasting lipoprotein and post-
prandial triacylglycerol responses to a low-carbohydrate diet
supplemented with n-3 fatty acids.  J Am Coll Nutr 2000,
19(3):383-391.
102. Meckling KA, Gauthier M, Grubb R, Sanford J: Effects of a hypoca-
loric, low-carbohydrate diet on weight loss, blood lipids,
blood pressure, glucose tolerance, and body composition in
free-living overweight women.  Can J Physiol Pharmacol 2002,
80(11):1095-1105.
103. Westman EC, Yancy WS, Edman JS, Tomlin KF, Perkins CE: Effect of
6-month adherence to a very low carbohydrate diet pro-
gram.  Am J Med 2002, 113(1):30-36.
104. Dashti HM, Bo-Abbas YY, Asfar SK, Mathew TC, Hussein T, Behba-
hani A, Khoursheed MA, Al-Sayer HM, Al-Zaid NS: Ketogenic dietPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nutrition & Metabolism 2005, 2:31 http://www.nutritionandmetabolism.com/content/2/1/31
Page 17 of 17
(page number not for citation purposes)
modifies the risk factors of heart disease in obese patients.
Nutrition 2003, 19(10):901-902.
105. Dashti HM, Mathew TC, Hussein T, Asfar SK, Behbahani A, Khour-
sheed MA, Al-Sayer HM, Bo-Abbas YY, Al-Zaid NS: Long-term
effects of a ketogenic diet in obese patients.  Exp Clin Cardiol
2004, 9(3):200-205.
106. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ: Com-
parison of the Atkins, Ornish, Weight Watchers, and Zone
diets for weight loss and heart disease risk reduction: a ran-
domized trial.  Jama 2005, 293(1):43-53.
107. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA: A randomized trial
comparing a very low carbohydrate diet and a calorie-
restricted low fat diet on body weight and cardiovascular risk
factors in healthy women.  J Clin Endocrinol Metab 2003,
88(4):1617-1623.
108. Volek JS, Sharman MJ, Gomez AL, Judelson DA, Rubin MR, Watson
G, Sokmen B, Silvestre R, French DN, Kraemer WJ: Comparison of
energy-restricted very low-carbohydrate and low-fat diets
on weight loss and body composition in overweight men and
women.  Nutr Metab (Lond) 2004, 1(1):13.
109. Brehm BJ, Spang SE, Lattin BL, Seeley RJ, Daniels SR, D'Alessio DA:
The role of energy expenditure in the differential weight loss
in obese women on low-fat and low-carbohydrate diets.  J Clin
Endocrinol Metab 2004.
110. Meckling KA, O'Sullivan C, Saari D: Comparison of a low-fat diet
to a low-carbohydrate diet on weight loss, body composition,
and risk factors for diabetes and cardiovascular disease in
free-living, overweight men and women.  J Clin Endocrinol Metab
2004, 89(6):2717-2723.
111. Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Wil-
liams M, Gracely EJ, Samaha FF: The effects of low-carbohydrate
versus conventional weight loss diets in severely obese
adults: one-year follow-up of a randomized trial.  Ann Intern
Med 2004, 140(10):778-785.
112. Yancy WSJ, Olsen MK, Guyton JR, Bakst RP, Westman EC: A low-
carbohydrate, ketogenic diet versus a low-fat diet to treat
obesity and hyperlipidemia: a randomized, controlled trial.
Ann Intern Med 2004, 140(10):769-777.